Fig. 2
From: Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy
RTKs are immunotherapeutic targets in pancreatic cancer. A Expression analysis of MET in pancreatic cancer and normal pancreatic tissue. B Expression summary of RTKs. All 26 RTKs significantly associated with the prognosis of immune “hot” pancreatic cancer were subjected to differential expression analysis. Up, upregulated; Ns, not significant. C Correlation analysis between the expression of MET and ICPs in pancreatic cancer. D Correlation summary between RTKs and ICPs. All 17 RTKs significantly upregulated in immune “hot” pancreatic cancer were subjected to correlation analysis